post huge beat rais deal payer expand access simplifi
distribut could temper magnitud upsid regardless bia
upsid revis guidanc cgm market remain significantli under-penetr
acceler best product futur pipelin
long term p-t
revenu y/i came forecast
consensu commerci avail three week quarter
beat broad base everi portion busi well ahead expect
includ us y/i ou y/i durabl y/i despit
headwind upgrad program sensor y/i ad significantli
new patient expect
gross margin came forecast
consensu manag note aggreg headwind quarter
hardwar obsolesc cost non-recur expens due product ramp
impact robust custom demand oper margin neg
expect consensu
manag increas full year revenu guidanc y/i increas
midpoint base bottom model appear
plenti room materi upsid
howev manag made clear potenti new distribut deal payer
pharmaci channel and/or subscript base model like medicare/som ou
geographi incorpor guidanc signific pricing/revenu
headwind expand patient access simplifi distribut would great
near long term strateg move though could temper magnitud
near term revenu upsid regardless believ bia clearli upsid revis
guidanc increas revenu forecast also significantli
increas beyond revenu forecast remain well consensu
expect expect exceed revis forecast
monster quarter clearli show cgm market acceler new
entrant associ signific market campaign appear help
cgm adopt still earli inning accurate/reli real-tim cgm
market best product pipelin continu view core long
term hold also continu convict broader type opportun
could drive signific upsid next year revis price target
base dcf analysi repres sale
pleas see page report import disclosur
believ make core growth stori attract
market dynam technolog differenti top-tier manag team
scalabl profit model competit potenti longer term price headwind
exist howev best pipelin industri believ remain clear
market leader forese futur wherev market goe
regulatori commerci mileston
us type cgm penetr continu
rapidli increas beyond
revenu growth approxim
thereaft
cgm penetr continu rapidli
increas toward standard care us
cgm begin adopt
revenu growth acceler
cgm penetr slow fail progress
toward standard care
price deterior faster expect
found headquart san diego california medic devic
compani focus design develop commerci continu glucos
monitor cgm system use peopl diabet use healthcar
provid hospit treatment patient without diabet dexcom
flagship offer today dexcom mobil patient diabet detect
trend track glucos pattern fda approv pediatr patient adult
move forward compani focus continu drive advanc cgm
technolog focus accuraci comfort connect longer term dexcom
goal replac tradit blood glucos monitor technolog
compani report thomson eikon cowen compani
cowen vs consensu mm except includ transmitt deferr headwindgross re-affirmed oper revenu metric mm except statement mm except per y/i nmnmnmnmshare count durabl revenu came forecast blow-out quarter ultim ad far new patient expect estim nearli market three week manag note upgrad program end repres headwind transmitt sensor revenu came forecast upsid driven sheer number new patient ad well strong trend among exist patient manag note stabl revenu came forecast consensu blow-out quarter y/i us y/i well expect estim ad nearli gross new patient quarter far highest compani histori market clearli acceler new entrant high competit market spend like help fuel growth manag significantli increas fy guidanc remain plenti upsid gross margin came forecast consensu manag note aggreg headwind non-recur expens due product ramp well obsolesc charg hardwar came forecast though well sale due revenu beat sg came forecast though well sale due revenu beat oper loss came better expect signific revenu upsid opex leverag partial off-set lower expect gross margin cowen
compani report thomson eikon cowen compani
mm except per share profit gener oper opex y/i excl non-intens non-intens invest earn per consensu estim mm except per share gross op cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
risk includ limit cgm penetr fail increas competit product
reduc competit moat profit push back materi new product
releas delay due regulatori hurdl trade signific premium
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc august et dissemin august et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
